37 results about "Cartilage Diseases" patented technology

The present application relates to a peptide having a cartilage regeneration effect and a use thereof, and provides a peptide comprising an amino acid sequence represented by SEQ ID NO: 1 or Arg (R)-Thr (T)-Leu (L)-Glu (E), a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.

The present disclosure relates generally to processes for providing compounds that can be used as inhibitors of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1), which inhibitors can be useful in treating or preventing soft bone diseases, such as hypophosphatasia (HPP).

Nanoparticles suitable for delivery of a cargo to a chondrocyte, and targeting peptides comprising a chondrocyte targeting sequence, are provided. Further provided are uses of the nanoparticles and targeting peptides, for example, in treating a joint or cartilage disease or disorder.

The present application relates to a peptide having a cartilage regeneration effect and uses thereof, and provides a peptide including an amino acid sequence of SEQ ID NO: 1 or Arg(R)-Tyr(Y)-Phe(F), a composition for cartilage regeneration, including the peptide, and a pharmaceutical composition for preventing or treating a cartilage disease, including the composition for cartilage regeneration as an active ingredient.

The present application relates to a peptide having a cartilage regeneration effect, and uses thereof, and provides a peptide including an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration, including the peptide, and a pharmaceutical composition for preventing or treating a cartilage disease, including the composition for cartilage regeneration as an active ingredient.

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions / disorders / diseases due to mutations or dysregulation of the Wnt pathway and / or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

The present invention relates to a pharmaceutical composition for treating cartilage damage diseases, comprising, as an active ingredient, magnetic nanoparticle-embedded nasal septal chondrocytes , and establishes a method for embedding magnetic nanoparticles into nasal septal chondrocytes and a method for preparing spheroids by culturing magnetic nanoparticle-embedded nasal septal chondrocytes. It was identified that the magnetic nanoparticle-embedded nasal septal chondrocytes prepared by the method of the present invention and spheroids prepared therefrom exhibit cartilage damage treatment activity while maintaining mobility in a magnetic field. In addition, since the activity is maintained even if spheroids are prepared by mixing magnetic nanoparticle-embedded nasal septal chondrocytes and nasal septal chondrocytes, the present invention can be effectively used as a composition for treating cartilage damage diseases that has an excellent therapeutic effect without causing side effects by having a significantly reduced addition ratio of the magnetic nanoparticles.

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions / disorders / diseases due to mutations or dysregulation of the Wnt pathway and / or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting / identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.

The present application relates to a peptide having a cartilage regeneration effect and a use thereof, and provides a peptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases comprising the composition for cartilage regeneration as an active ingredient.

The present application relates to a peptide having a cartilage regeneration effect and a use thereof, and provides a peptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases comprising the composition for cartilage regeneration as an active ingredient.

A pharmaceutical compositions includes GLP-1 and GLP-1 analogues inducing an anabolic stimulation of chondrocytes and a decreasing in chondrocyte catabolic including a decrease in cartilage matrix loss and cartilage degeneration for use in the treatment of cartilage disease. The composition induces cartilage regeneration and anabolic stimulation of chondrocytes, including chondrocyte proliferation and / or stem cell differentiation into chondrocytes.

The present invention relates to a pharmaceutical composition for preventing or treating cartilage disease or inflammatory joint disease and a method for preparing a chondrospheroid having chondrocyte differentiation ability. The present invention provides a pharmaceutical composition comprising a stem cell-derived spheroid as an active ingredient for preventing or treating cartilage disease or inflammatory joint disease, and a method for preparing a chondrospheroid having chondrocyte differentiation ability, the method comprising the steps of: Inoculating stem cells into a three-dimensional (3D) cell culture vessel made of a plastic material; treating the stem cells inoculated into the 3D cell culture vessel with a chondrocyte differentiation-inducing factor; culturing the stem cells treated with the chondrocyte differentiation-inducing factor to form chondrospheroids; and separating the formed chondrospheroids.

The present application relates to a peptide having a cartilage regeneration effect and a use thereof, and provides a peptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases comprising the composition for cartilage regeneration as an active ingredient.

The present application relates to a peptide having a cartilage regeneration effect and a use thereof, and provides a peptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases comprising the composition for cartilage regeneration as an active ingredient.

A pharmaceutical compositions includes GLP-1 and GLP-1 analogues inducing an anabolic stimulation of chondrocytes and a decreasing in chondrocyte catabolic including a decrease in cartilage matrix loss and cartilage degeneration for use in the treatment of cartilage disease. The composition induces cartilage regeneration and anabolic stimulation of chondrocytes, including chondrocyte proliferation and / or stem cell differentiation into chondrocytes.

This disclosure relates to orthopaedic implants and methods for restoring functionality to a joint. The implants described herein may be utilized during orthopaedic procedures and may be incorporated into a shoulder prosthesis for restoring functionality to shoulders having advanced cartilage disease. The disclosed implants may incorporate one or more fasteners formed together with a main body of the respective implant at a breakable connection. The fastener may be deployed during a surgical procedure, which may improve fixation of the implant at the surgical site.

Provided are dual-affinity fusion proteins including an affibody domain specific for a therapeutic protein, and including a localization domain specific for a structural bone component. The therapeutic protein can include bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), or glial derived neurotrophic factor (GDNF). Also provided are compositions that include the dual-affinity fusion proteins, affibodies and the corresponding therapeutic proteins, and / or a medical material used to treat a wound, or a bone or cartilage injury or disease. Also provided are methods of using the compositions, for example to treat bone injuries, bone diseases, cartilage injuries, cartilage diseases, and wounds. In some examples, the composition includes at least two different dual-affinity fusion proteins specific for the same therapeutic protein, but have different disassociation constants (KD).

The present application relates to a peptide having a cartilage regeneration effect and a use thereof, and provides a peptide comprising an amino acid sequence represented by SEQ ID NO: 1 or Arg (R)-Leu (L)-Arg (R)-Ser (S), a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.

A method for treating hypophosphatasia (HPP) is provided herein, comprising administering a therapeutically effective dose of an ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) inhibitor. A method for using an ENPP1 inhibitor to treat or prevent cartilage disease is disclosed herein. In some embodiments, the cartilage disease is hypophosphatasia. Ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) is an extracellular enzyme that hydrolyzes ATP to PPi and AMP in the extracellular space.

The present application relates to a peptide having a cartilage regeneration effect and a use thereof, and provides: a peptide comprising an amino acid sequence represented by Glu (E)-Tyr (Y)-Phe (F)-Trp (W) or Arg (R)-Thr (T)-Leu (L), a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.

The invention relates to a peptide with a cartilage regeneration effect and application thereof. Provided are a peptide comprising an amino acid sequence represented by SEQ ID NO: 1 or Arg (R)-Tyr (Y)-Phe (F), a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases comprising the composition for cartilage regeneration as an active ingredient.

The present application relates to a peptide having a cartilage regeneration effect, and uses thereof, and provides a peptide including an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration, including the peptide, and a pharmaceutical composition for preventing or treating a cartilage disease, including the composition for cartilage regeneration as an active ingredient.

The present application relates to a peptide having a cartilage regeneration effect, and uses thereof, and provides a peptide including an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration, including the peptide, and a pharmaceutical composition for preventing or treating a cartilage disease, including the composition for cartilage regeneration as an active ingredient.

To provide a method for regenerating bone and / or cartilage, and a method for treating and / or preventing a bone and / or cartilage disease.SOLUTION: Provided are a composition for regenerating bone and / or cartilage which contains culture supernatant of an M2 macrophage, and a method for manufacturing a composition for regenerating bone and / or cartilage which includes culturing an M2 macrophage and recovering culture supernatant. Provided are a composition for treating and / or preventing a bone and / or cartilage disease which contains culture supernatant of an M2 macrophage, and a method for manufacturing a composition for treating and / or preventing a bone and / or cartilage disease which includes culturing M2 macrophage and recovering culture supernatant.SELECTED DRAWING: Figure 3

To provide a composition for maintaining bone and / or cartilage health, or for preventing, alleviating and / or treating bone and / or cartilage disorders.SOLUTION: There is provided a composition comprising Vitamin D and oleuropein for use to enhance the stimulation of bone formation by oleuropein, wherein the composition comprises between 800 and 1200IU of Vitamin D and between 0. 01mg and 1g of oleuropein. The composition may further comprise one or more bioactive molecules selected from the group consisting of antioxidants, anti-inflammatory compounds, fatty acids, prebiotic fibers, probiotics, glucosamine, chondroitin sulfate, minerals, trace elements and vitamins.SELECTED DRAWING: None

The invention discloses a preparation method of a doped nano-enzyme preparation for treating and diagnosing cartilage diseases as well as a product and application of the doped nano-enzyme preparation. The preparation method comprises the following steps: doping miscellaneous metals into single metal oxide nano-enzyme to obtain doped nano-enzyme; performing positive electricity modification on the doped nano enzyme to prepare an injectable preparation; injectable formulations are used for the treatment, alleviation and diagnosis of cartilage disease. According to the nano-enzyme preparation for cartilage prepared by the invention, the medication frequency can be reduced, and the injection infection risk and economic burden can be reduced; the continuous anti-inflammatory effect is enhanced, and the protection effect on the body is prolonged; physiological toxicity is avoided; the multi-enzyme activity can be regulated and designed, and personalized customization is carried out aiming at diseases; the method can be used for rapidly diagnosing the cartilage health degree of the joint pathological section.

The present application relates to a peptide having a cartilage regeneration effect and a use thereof, and provides a peptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases comprising the composition for cartilage regeneration as an active ingredient.

The invention relates to application of a composition in preparation of drugs for improving diseases related to mitochondrial dysfunction, and belongs to the technical field of medicine preparation, and the composition comprises artemisia desertorum, turnip and menthol. Analysis and research on the composition formed by artemisia desertorum, turnip and menthol show that the composition can improve the mitochondrial membrane potential, reduce the active oxygen level in cartilage cells, improve the ATP content of mitochondria, promote the structural recovery of mitochondria and improve the expression level of mitochondrial fusion and division related protein, and the mitochondrial fusion and division related protein expression level can be improved. The cartilage disease caused by mitochondrial dysfunction is obviously improved.

The present application relates to a peptide having a cartilage regeneration effect and a use thereof, and provides a peptide comprising an amino acid sequence represented by SEQ ID NO: 1 or Glu (E)-Asp (D)-Asp (D), a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.